FTSE 100 news / Companies and sectors / Pharma and healthcare / 5 October 2026
Pharma and healthcare: sector news on Monday 5 October 2026
Average tone +3.3 (positive) across 5 companies with relevant coverage, from 21 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +4.5 | 11 | Coverage was mostly positive on pipeline news, including faster FDA review of a bladder cancer regimen, positive phase 3 COPD results and an Indian panel nod for camizestrant. |
| GSK | +6.0 | 5 | Coverage centred on GSK's dealmaking, including a completed USD 2.3 billion acquisition and a $750 million myeloma therapy purchase, which adds to its pipeline. |
| Convatec | +5.2 | 2 | Coverage centred on the launch of Cure Aqua in North America and a look at whether Convatec can sustain its margin progress while its buyback continues. |
| Haleon | +2.0 | 2 | Coverage was about Haleon appointing Vandana Chamaria as Head of Oral Health for India and South Asia. |
| Smith & Nephew | −1.3 | 1 | The only relevant coverage concerned Smith & Nephew facing a USD 350 million debt redemption. |
Strongest stories in the sector
- +10.0 AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
Positive phase 3 COPD data with up to 34% fewer exacerbations. - +9.7 FDA Speeds Review of AstraZeneca Bladder Cancer Regimen
FDA accelerated review of bladder cancer regimen is a clear positive. - −9.2 BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
Heart drug trial with Ionis missed its goal, a clear setback. - +7.5 AstraZeneca Gets CDSCO Panel Nod to Import, Market Camizestrant for Breast Cancer
Indian panel backs camizestrant import and marketing, supporting approval prospects. - +7.5 RAPT stock ends as GSK completes USD 2.3 billion deal
GSK completes USD 2.3 billion acquisition, strengthening its pipeline. - +7.0 ConvaTec stock launches Cure Aqua in North America
Product launch in North America expands its offering and market reach. - +7.0 GSK agrees to acquire myeloma therapy. GSK stock costs EUR 20.83
GSK acquiring a myeloma therapy expands its oncology pipeline. - +6.7 GSK (NYSE: GSK) Strikes $750 Million Deal To Acquire Trispecific T-Cell Engager From ChImagen Biosciences For Multiple Myeloma
$750 million deal adds a multiple myeloma T-cell engager. - +6.3 Summit, AstraZeneca and Daiichi Sankyo Plan Phase III Trial in Triple-Negative Breast Cancer
Planned phase III trial in breast cancer with partners shows pipeline progress. - +5.8 DTI, AstraZeneca deepen Philippines clinical
Partnership to expand clinical research in the Philippines is a modest positive. - +5.5 DTI, AstraZeneca push PH as clinical research, life sciences hub
Same DTI partnership to build life sciences hub; mildly positive. - −3.7 GSK stock trades at GBp 1,779.50 after Nuvalent deal risks emerge
Share price story highlights risks emerging around the Nuvalent deal.
Pharma and healthcare: every day · FTSE 100 overview for the day